Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

A role for glucagon-like peptide-1 in the central regulation of feeding

Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124

Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R. A., & Schmiegel, W. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 834

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793

Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man

Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670

Hamster preproglucagon contains the sequence of glucagon and two related peptides

Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649

Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats

Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597

Attenuated GLP-1 secretion in obesity: cause or consequence

Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V (1996) · Gut · doi:10.1136/gut.38.6.916 · Cited by 394

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes

ten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Barkhof, F., Deacon, C. F., Holst, J. J., Konrad, R. J., Sloan, J. H., Drent, M. L., Diamant, M., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3754-x · Cited by 108

Effects of JNJ‐38431055, a novel GPR119 receptor agonist, in randomized, double‐blind, placebo‐controlled studies in subjects with type 2 diabetes

Katz, L., Gambale, J. J., Rothenberg, P., Vanapalli, S. R., Vaccaro, N. M., Xi, L., Sarich, T. C., & Stein, P. P. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01587.x · Cited by 110

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1

Parkes, D. G., Mace, K. F., & TRAUTMANN, M. E. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741580 · Cited by 114

Effects of dietary fat on appetite and energy intake in health and obesity — Oral and gastrointestinal sensory contributions

Little, T. J., & Feinle‐Bisset, C. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.04.038 · Cited by 110

Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant Rats

Burkey, B. F., Li, X., Bolognese, L., Balkan, B., Mone, M. D., Russell, M., Hughes, T. E., & Wang, P. R. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087064 · Cited by 108

Effect of Weight Loss by Diet or Gastric Bypass Surgery on Peptide YY3–36 Levels

Oliván, B., Teixeira, J. A., Bose, M., Bawa, B., Chang, T. C., Summe, H., Lee, H., & Laferrère, B. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a6cdb0 · Cited by 104

Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion

Lu, V. B., Gribble, F. M., & Reimann, F. M. (2021) · Nutrients · doi:10.3390/nu13030883 · Cited by 111

Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter

Larsen, P. J., & Holst, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.026 · Cited by 108

Glucagon‐like Peptide‐2 and the Regulation of Intestinal Growth and Function

Brubaker, P. L. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170055 · Cited by 132

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

Holst, J. J. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/eoed.9.1.155.32952 · Cited by 104

No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects

Sørensen, L. B., Flint, A., Raben, A., Hartmann, B., Holst, J. J., & Astrup, A. V. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802247 · Cited by 102

Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes

Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 103

Glucagon-like peptide-1 (7–36) amide: a central regulator of satiety and interoceptive stress

van Dijk, G., & Thiele, T. E. (1999) · Neuropeptides · doi:10.1054/npep.1999.0053 · Cited by 99

Glucagon-like peptides 1 and 2 in health and disease: A review

Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99

Harnessing glucagon‐like peptide‐1 receptor agonists for the pharmacological treatment of overweight and obesity

Burcelin, R., & Gourdy, P. (2016) · Obesity Reviews · doi:10.1111/obr.12465 · Cited by 99

Gut hormones and appetite control

Hameed, S., Dhillo, W. S., & Bloom, S. R. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2008.01492.x · Cited by 102

GLP‐1: physiological effects and potential therapeutic applications

Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 99

Exendin-4 decreases amphetamine-induced locomotor activity

Erreger, K., Davis, A. R., Poe, A. M., Greig, N. H., Stanwood, G. D., & Galli, A. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.03.014 · Cited by 96

Intestinal glucagon-like peptide-1 effects on food intake: physiological relevance and emerging mechanisms

Krieger, J.-P. (2020) · Peptides · doi:10.1016/j.peptides.2020.170342 · Cited by 91

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

Flint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91

Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core

Fortin, S. M., & Roitman, M. F. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.03.019 · Cited by 88

Decreased Glucagon‐like Peptide 1 Release after Weight Loss in Overweight/Obese Subjects

Adam, T. C., Jocken, J. W. E., & Westerterp‐Plantenga, M. S. (2005) · Obesity Research · doi:10.1038/oby.2005.80 · Cited by 91

Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI)

Parkinson, J. R. C., Chaudhri, O. B., Kuo, Y., Field, B. C. T., Herlihy, A. H., Dhillo, W. S., Ghatei, M. A., Bloom, S. R., & Bell, J. D. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.09.047 · Cited by 89

The Emerging Role of Polyphenols in the Management of Type 2 Diabetes

Wang, Y., Alkhalidy, H., & Liu, D. (2021) · Molecules · doi:10.3390/molecules26030703 · Cited by 88

Glucagon and Glucagon-Like Peptide Receptors as Drug Targets

Estall, J. L., & Drucker, D. J. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776873671 · Cited by 88

Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging

Chaudhri, O. B., Parkinson, J. R. C., Kuo, Y., Druce, M. R., Herlihy, A. H., Bell, J. D., Dhillo, W. S., Stanley, S. A., Ghatei, M. A., & Bloom, S. R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.033 · Cited by 87

Peripheral tissue–brain interactions in the regulation of food intake

López, M., Tovar, S. A., Vazquez, M. J., Williams, L. M., & Diéguez, C. (2007) · Proceedings of The Nutrition Society · doi:10.1017/s0029665107005368 · Cited by 87

Stimulation of incretin secretion by dietary lipid: is it dose dependent?

Yoder, S. M., Yang, Q., Kindel, T. L., & Tso, P. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90601.2008 · Cited by 87

Gastric Pacing for Morbid Obesity: Plasma Levels of Gastrointestinal Peptides and Leptin

Cigaina, V., & Hirschberg, A. L. (2003) · Obesity Research · doi:10.1038/oby.2003.195 · Cited by 86

Fermentable and Nonfermentable Fiber Supplements Did Not Alter Hunger, Satiety or Body Weight in a Pilot Study of Men and Women Consuming Self-Selected Diets

Howarth, N. C., Saltzman, E. J., McCrory, M. A., Greenberg, A. S., Ausman, L. M., Kramer, D. G., Roberts, S. B., & Dwyer, J. T. (2003) · Journal of Nutrition · doi:10.1093/jn/133.10.3141 · Cited by 85

Gastrointestinal hormones: the regulation of appetite and the anorexia of ageing

Moss, C., Dhillo, W. S., Frost, G. S., & Hickson, M. (2011) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2011.01211.x · Cited by 89

Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men

Feinle, C., Chapman, I. M., Wishart, J. M., & Horowitz, M. (2002) · Peptides · doi:10.1016/s0196-9781(02)00087-6 · Cited by 81

Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity

Anandhakrishnan, A., & Korbonits, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.572 · Cited by 83

Postprandial changes in gut regulatory peptides in gastric bypass patients

Holdstock, C., Zethelius, B., Sundbom, M., Karlsson, F. A., & Engström, B. E. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.157 · Cited by 75

Incretin hormones - an update

Holst, J. J., & Ørskov, C. (2001) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/clb.61.234.75.85 · Cited by 77

Towards a comprehensive theory of obesity and a healthy diet: The causal role of oxidative stress in food addiction and obesity

Tobore, T. O. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112560 · Cited by 73

The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion

Hjørne, A. P., Modvig, I. M., & Holst, J. J. (2022) · Metabolites · doi:10.3390/metabo12050420 · Cited by 79

Combination of the Dipeptidyl Peptidase IV Inhibitor LAF237 [(S)-1-[(3-Hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the Angiotensin II Type 1 Receptor Antagonist Valsartan [N-(1-Oxopentyl)-N-[[2′-(1 H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl]methyl]-l-valine] Enhances Pancreatic Islet Morphology and Function in a Mouse Model of Type 2 Diabetes

Cheng, Q., Law, P. K., de Gasparo, M., & Leung, P. S. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.142703 · Cited by 73

Systematic literature review shows that appetite rating does not predict energy intake

Holt, G., Owen, L., Till, S., Cheng, Y., Grant, V., Harden, C. J., & Corfe, B. M. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1246414 · Cited by 73

Glucagon-like peptide-1 and glucagon-like peptide-2

Baggio, L. L., & Drucker, D. J. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.001 · Cited by 76

Vision and Eating Behavior

Linne, Y. M., Barkeling, B., Rössner, S., & Rooth, P. (2002) · Obesity Research · doi:10.1038/oby.2002.15 · Cited by 72

New therapies for obesity

Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73

The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: Concept and physiological functions

Girard, J. R. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.09.001 · Cited by 75

The effect of Korean pine nut oil (PinnoThin™) on food intake, feeding behaviour and appetite: A double-blind placebo-controlled trial

Hughes, G. M., Boyland, E. J., Williams, N. J., Mennen, L. I., Scott, C. E., Kirkham, T. C., Harrold, J. A., Keizer, H. G., & Halford, J. C. G. (2008) · Lipids in Health and Disease · doi:10.1186/1476-511x-7-6 · Cited by 70

Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs

Carmina, E., & Longo, R. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185921 · Cited by 78

Vagal Afferents Mediate Early Satiation and Prevent Flavour Avoidance Learning in Response to Intraperitoneally Infused Exendin‐4

Labouesse, M. A., Weber‐Stadlbauer, U., Weber, E., Arnold, M., Langhans, W., & Pacheco‐López, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02364.x · Cited by 71

Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1

Hellström, P. M., & Näslund, E. B. (2001) · Physiology & Behavior · doi:10.1016/s0031-9384(01)00618-7 · Cited by 71

Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs

Nishizawa, M., Moore, M. C., Shiota, M., Gustavson, S. M., Snead, W. L., Neal, D. W., & Cherrington, A. D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00503.2002 · Cited by 69

Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis

Tzang, C.-C., Wu, P.-H., Luo, C.-A., Chen, Z.-T., Lee, Y.-T., Huang, E. S., Kang, Y.-F., Lin, W.-C., Tzang, B.-S., & Hsu, T.-C. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103680 · Cited by 73

Targeting Intermediary Metabolism in the Hypothalamus as a Mechanism to Regulate Appetite

Lopaschuk, G. D., Ussher, J. R., & Jaswal, J. S. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002428 · Cited by 71

Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective

Michałowska, J., Miller‐Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 77

Appetite- and Weight-Regulating Neuroendocrine Circuitry in Hypothalamic Obesity

Gan, H., Cerbone, M., & Dattani, M. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad033 · Cited by 75

Liraglutide, a human glucagon‐like peptide‐1 analogue, stimulates AKT‐dependent survival signalling and inhibits pancreatic β‐cell apoptosis

Kapodistria, K., Tsilibary, E.-P. C., Kotsopoulou, E. S., Moustardas, P., & Kitsiou, P. V. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13259 · Cited by 72

Intestinal GLP-1 and satiation: from man to rodents and back

Steinert, R. E., Beglinger, C., & Langhans, W. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.172 · Cited by 72

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

Agersø, H., & Vicini, P. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(03)00073-3 · Cited by 66

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential

Torekov, S. S., Madsbad, S., & Holst, J. J. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00860.x · Cited by 65

Effects of peripheral administration of synthetic human glucose‐dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes

Daousi, C., Wilding, J. P. H., Aditya, S., Durham, B. H., Cleator, J., Pinkney, J. H., & Ranganath, L. R. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03451.x · Cited by 64

Effects of appetite, BMI, food form and flavor on mastication: almonds as a test food

Frecka, J. M., Hollis, J., & Mattes, R. D. (2007) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602838 · Cited by 65

Low‐dose Pramlintide Reduced Food Intake and Meal Duration in Healthy, Normal‐Weight Subjects

Chapman, I. M., Parker, B. A., Doran, S., Feinle‐Bisset, C., Wishart, J. M., Lush, C. W., Chen, K. S., LaCerte, C., Burns, C. M., McKay, R., et al. (2007) · Obesity · doi:10.1038/oby.2007.626 · Cited by 65

Peripheral signalling involved in energy homeostasis control

Lancha, A., Frühbeck, G., & Gómez‐Ambrosi, J. (2012) · Nutrition Research Reviews · doi:10.1017/s0954422412000145 · Cited by 66

The role of gastrointestinal vagal afferent fibres in obesity

Kentish, S. J., & Page, A. J. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.278226 · Cited by 63

CNS GLP-1 regulation of peripheral glucose homeostasis

Sandoval, D. A. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.04.018 · Cited by 59

Peripheral Glucagon-like Peptide-1 (GLP-1) and Satiation

Punjabi, M., Arnold, M., Geary, N., Langhans, W., & Pacheco‐López, G. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.02.038 · Cited by 62

Unraveling the Science of Incretin Biology

Nauck, M. A. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.012 · Cited by 62

Role of motility in chronic diarrhoea

Spiller, R. E. (2006) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00836.x · Cited by 61

Incretin‐based therapies

Stonehouse, A. H., Darsow, T., & Maggs, D. G. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00143.x · Cited by 65

Postprandial effects of polydextrose on satiety hormone responses and subjective feelings of appetite in obese participants

Olli, K., Salli, K. M., Alhoniemi, E. J., Saarinen, M., Ibarra, A., Vasankari, T. J., Rautonen, N., & Tiihonen, K. (2015) · Nutrition Journal · doi:10.1186/1475-2891-14-2 · Cited by 64

DIGESTIVE PHYSIOLOGY OF THE PIG SYMPOSIUM: Secretion of gastrointestinal hormones and eating control1

Steinert, R. E., Feinle‐Bisset, C., Geary, N., & Beglinger, C. (2013) · Journal of Animal Science · doi:10.2527/jas.2012-6022 · Cited by 62

The entero-insular axis: implications for human metabolism

Ranganath, L. R. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.008 · Cited by 58

Liraglutide Prevents Hypoadiponectinemia-Induced Insulin Resistance and Alterations of Gene Expression Involved in Glucose and Lipid Metabolism

Li, L., Zong-yuan, M. I. A. O., Liu, R., Yang, M., Liu, H., & Yang, G. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00051 · Cited by 55

Regulation of energy homeostasis by peripheral signals

Woods, S. C., Benoit, S. C., Clegg, D. J., & Seeley, R. J. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.004 · Cited by 56

Nutrient-stimulated glucagon-like peptide 1 release after body-weight loss and weight maintenance in human subjects

Adam, T. C., Lejeune, M. P. G. M., & Westerterp‐Plantenga, M. S. (2006) · British Journal Of Nutrition · doi:10.1079/bjn20051614 · Cited by 54

GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat

Bozkurt, A., Näslund, E. B., Holst, J. J., & Hellström, P. M. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00095-2 · Cited by 52

Regulation of Memory Function by Feeding-Relevant Biological Systems: Following the Breadcrumbs to the Hippocampus

Suarez, A. N., Noble, E. E., & Kanoski, S. E. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00101 · Cited by 55

Incretins, diabetes, and bariatric surgery: a review

Fetner, R., McGinty, J., Russell, C. D., Pi-Sunyer, X., & Laferrère, B. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2005.09.001 · Cited by 52

Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide

Dungan, K. M., & Buse, J. B. (2005) · Clinical Diabetes · doi:10.2337/diaclin.23.2.56 · Cited by 50

Anticipatory and consummatory effects of (hedonic) chocolate intake are associated with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese adults

Rigamonti, A. E., Piscitelli, F., Aveta, T., Agosti, F., Col, A. D., Bini, S., Cella, S. G., Marzo, V. D., & Sartório, A. (2015) · Food & Nutrition Research · doi:10.3402/fnr.v59.29678 · Cited by 52

Hypoxia-Related Hormonal Appetite Modulation in Humans during Rest and Exercise: Mini Review

Debevec, T. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00366 · Cited by 49

Short-term effects of sibutramine (ReductilTM) on appetite and eating behaviour and the long-term therapeutic outcome

Barkeling, B., Elfhag, K., Rooth, P., & Rössner, S. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802298 · Cited by 49

New treatments in type 2 diabetes: a focus on the incretin‐based therapies

Barnett, A. H. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03396.x · Cited by 50

Detailed characterization of incretin cell distribution along the human small intestine

Guedes, T. P., Martins, S., Costa, M. M., Pereira, S. S., Morais, T., Santos, A., Nora, M. C., & Monteiro, M. P. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2015.02.011 · Cited by 46

Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes

Rhee, N. A., Vilsbøll, T., & Knop, F. K. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01505.x · Cited by 47

Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis

Dong, C. X., & Brubaker, P. L. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.185 · Cited by 45

Anorexigenic Effects of GLP-1 and Its Analogues

Gallwitz, B. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_8 · Cited by 45

Anorexia of Aging and Gut Hormones

Atalayer, D. (2013) · Aging and Disease · doi:10.14336/ad.2013.0400264 · Cited by 47

Women with bulimia nervosa exhibit attenuated secretion of glucagon-like peptide 1, pancreatic polypeptide, and insulin in response to a meal

Naessén, S., Carlström, K., Holst, J. J., Hellström, P. M., & Hirschberg, A. L. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.014837 · Cited by 47

Effect of Laparoscopic Sleeve Gastrectomy on Fasting Gastrointestinal, Pancreatic, and Adipose-Derived Hormones and on Non-Esterified Fatty Acids

Farey, J. E., Preda, T. C., Fisher, O. M., Levert‐Mignon, A., Stewart, R. L., Karsten, E., Herbert, B. R., Swarbrick, M. M., & Lord, R. V. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2302-1 · Cited by 46

The role of pancreatic polypeptide in the regulation of energy homeostasis

Khandekar, N., Berning, B. A., Sainsbury, A., & Lin, S. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.028 · Cited by 51

Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: A Review of Emerging Therapies for Type 2 Diabetes

Kendall, D. M., Kim, D. S., & Maggs, D. G. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.385 · Cited by 44

Gut Hormones and Leptin: Impact on Energy Control and Changes After Bariatric Surgery—What the Future Holds

Michalakis, K. G., & le Roux, C. W. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0698-9 · Cited by 44

The incretin system ABCs in obesity and diabetes – novel therapeutic strategies for weight loss and beyond

João, A. L., Reis, F., & Fernandes, R. (2016) · Obesity Reviews · doi:10.1111/obr.12421 · Cited by 47

Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial

Basolo, A., Burkholder, J., Osgood, K., Graham, A. L., Bundrick, S. C., Frankl, J. A., Piaggi, P., Thearle, M. S., & Krakoff, J. A. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.017 · Cited by 46

Pharmacological Approaches for the Treatment of Obesity

Fern??ndez-L??pez, J.-A., Remesar, X., Foz, M., & Alemany, M. (2002) · Drugs · doi:10.2165/00003495-200262060-00005 · Cited by 42

New Targets for Drug Treatment of Obesity

Valsamakis, G., Konstantakou, P., & Mastorakos, G. P. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104735 · Cited by 41

Decreased Basal Levels of Glucagon-Like Peptide-1 after Weight Loss in Obese Subjects

de Luis, D. A., Sagrado, M. G., Conde, R., Aller, R., & Izaola, O. (2007) · Annals of Nutrition and Metabolism · doi:10.1159/000103273 · Cited by 41

Pleiotropic Actions of the Incretin Hormones

McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 42

Increasing doses of fiber do not influence short-term satiety or food intake and are inconsistently linked to gut hormone levels

Willis, H., Thomas, W. T. B., Eldridge, A. L., Harkness, L., Green, H., & Slavin, J. L. (2010) · Food & Nutrition Research · doi:10.3402/fnr.v54i0.5135 · Cited by 39

Impact of leucine on energy balance

McAllan, L., Cotter, P. D., Roche, H. M., Korpela, R., & Nilaweera, K. N. (2012) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-012-0170-2 · Cited by 41

Vision and Eating Behavior in Obese Subjects

Barkeling, B., Linne, Y. M., Melin, E., & Rooth, P. (2003) · Obesity Research · doi:10.1038/oby.2003.21 · Cited by 40

True

Flint, A., Raben, A., Astrup, A. V., Ersbøll, A. K., & Holst, J. J. (2001) · International Journal of Obesity · doi:10.1038/sj/ijo/0801627

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384

Rapid Publication Glucagon-like Peptide 1 Promotes Satiety and Suppresses Energy Intake in Humans

Invest, J. C., Flint, A., Raben, A., Astrup, A., & Holst, J. J. (2016)

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men

Näslund, E. B., Gutniak, M., Skogar, S., Rössner, S., & Hellström, P. M. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.3.525 · Cited by 304